{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:41:19Z","timestamp":1788352879110,"version":"build-2803163510"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>The medical management of inflammatory bowel disease [IBD] has become increasingly targeted, through the identification of specific immune mediators involved in its pathogenesis. IL-23 is an inflammatory cytokine involved in both innate and adaptive immunity, which has been identified as a therapeutic target in Crohn\u2019s disease [CD] and ulcerative colitis [UC] through its upstream inhibition of the T helper 17 [Th17] pathway. We sought to review available data on the efficacy of IL-23 inhibitors in the treatment of IBD and the potential for clinical and molecular predictors of response to facilitate a personalised medicine approach with these agents.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We reviewed and summarised available clinical trial data on the use of the IL-23 inhibitors risankizumab, brazikumab, mirikizumab, and guselkumab in the treatment of IBD, as well as the evidence from studies of these agents in IBD and other immune-mediated conditions which might inform prediction of response to IL-23 inhibition.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Early clinical trials have demonstrated promising results following both induction and maintenance therapy with IL-23 inhibitors in CD and UC. Pre- and post-treatment levels of IL-22 and post-treatment levels of IL-17 have been identified as potential molecular predictors of response to therapy, in several studies. No significant clinical predictors of response have been identified thus far.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>IL-23 antagonism is a promising therapeutic approach in IBD. Further exploration of molecular and clinical predictors of response may identify patients most likely to benefit from these medications.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjab190","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T19:12:08Z","timestamp":1635534728000},"page":"ii73-ii94","source":"Crossref","is-referenced-by-count":25,"title":["Personalised Medicine with IL-23 Blockers: Myth or Reality?"],"prefix":"10.1093","volume":"16","author":[{"given":"Zo\u00eb S","family":"Gottlieb","sequence":"first","affiliation":[{"name":"Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E","family":"Sands","sequence":"additional","affiliation":[{"name":"Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,1]]},"reference":[{"key":"2022051713564643300_CIT0001","first-page":"23","article-title":"Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?","volume":"13","author":"Viscido","year":"2019","journal-title":"Biologics"},{"key":"2022051713564643300_CIT0002","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/ibd\/izz059","article-title":"The role of early biologic therapy in inflammatory bowel disease.","volume":"25","author":"Berg","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2022051713564643300_CIT0003","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"UNIFI Study Group. Ustekinumab as induction and maintenance therapy for ulcerative colitis.","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"2022051713564643300_CIT0004","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"UNITI\u2013IM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease.","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"2022051713564643300_CIT0005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41575-018-0084-8","article-title":"IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting.","volume":"16","author":"Moschen","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2022051713564643300_CIT0006","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","article-title":"Interleukin-23: as a drug target for autoimmune inflammatory diseases.","volume":"135","author":"Tang","year":"2012","journal-title":"Immunology"},{"key":"2022051713564643300_CIT0007","doi-asserted-by":"crossref","first-page":"611256","DOI":"10.3389\/fimmu.2021.611256","article-title":"The IL23-IL17 immune axis in the treatment of ulcerative colitis: successes, defeats, and ongoing challenges.","volume":"12","author":"Noviello","year":"2021","journal-title":"Front Immunol"},{"key":"2022051713564643300_CIT0008","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis.","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J Invest Dermatol"},{"key":"2022051713564643300_CIT0009","doi-asserted-by":"crossref","first-page":"609395","DOI":"10.1155\/2013\/609395","article-title":"Th17-associated cytokines as a therapeutic target for steroid-insensitive asthma.","volume":"2013","author":"Morishima","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"2022051713564643300_CIT0010","doi-asserted-by":"crossref","first-page":"295132","DOI":"10.1155\/2013\/295132","article-title":"IL-17 in the rheumatologist\u2019s line of sight.","volume":"2013","author":"Truchetet","year":"2013","journal-title":"Biomed Res Int"},{"key":"2022051713564643300_CIT0011","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bpg.2018.05.016","article-title":"Can IL-23 be a good target for ulcerative colitis?","volume":"32\u20133","author":"Allocca","year":"2018","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2022051713564643300_CIT0012","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1084\/jem.20030896","article-title":"Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation.","volume":"198","author":"Murphy","year":"2003","journal-title":"J Exp Med"},{"key":"2022051713564643300_CIT0013","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn\u2019s disease: a randomised, double-blind, placebo-controlled phase 2 study.","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet"},{"key":"2022051713564643300_CIT0014","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S2468-1253(18)30233-4","article-title":"Risankizumab in patients with moderate to severe Crohn\u2019s disease: an open-label extension study.","volume":"3","author":"Feagan","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2022051713564643300_CIT0015","article-title":"Risankizumab induction therapy in patients with moderate-to-severe Crohn\u2019s disease: results from the advance and motivate phase 3 studies,","volume-title":"Digestive Disease Week","author":"D\u2019Haens","year":"2021"},{"key":"2022051713564643300_CIT0016","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.gastro.2017.03.049","article-title":"Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn\u2019s disease: a phase 2a study.","volume":"153","author":"Sands","year":"2017","journal-title":"Gastroenterology"},{"key":"2022051713564643300_CIT0017","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomised trial of patients with active ulcerative colitis.","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"2022051713564643300_CIT0018","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0016-5085(21)00835-0","article-title":"Efficacy and safety of mirikizumab after 52-weeks maintenance treatment in patients with moderate-to-severe Crohn\u2019s disease.","volume":"160","author":"Sands","year":"2021","journal-title":"Gastroenterology"},{"key":"2022051713564643300_CIT0019","doi-asserted-by":"crossref","first-page":"S-350","DOI":"10.1016\/S0016-5085(21)01553-5","article-title":"The effect of guselkumab induction therapy on inflammatory biomarkers in patients with moderately to severely active Crohn\u2019s disease: week 12 results from the phase 2 GALAXI 1 study.","volume":"160","author":"Sands","year":"2021","journal-title":"Gastroenterology"},{"key":"2022051713564643300_CIT0020","first-page":"S","article-title":"The effect of guselkumab induction therapy on endoscopic outcome measures in patients with moderately to severely active Crohn\u2019s disease: week 12 results from the phase 2 GALAXI 1 study.","volume":"160","author":"D\u2019Haens","year":"2021","journal-title":"Gastroenterology"},{"key":"2022051713564643300_CIT0021","doi-asserted-by":"crossref","first-page":"101604","DOI":"10.1016\/j.bpg.2019.02.006","article-title":"IL12\/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn\u2019s disease?","volume":"38\u20139","author":"Ma","year":"2019","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"2022051713564643300_CIT0022","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis [UltIMMa-1 and UltIMMa-2]: results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"2022051713564643300_CIT0023","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med"},{"key":"2022051713564643300_CIT0024","author":"Janssen Research & Development.","year":"2021"},{"key":"2022051713564643300_CIT0025","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","article-title":"Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn\u2019s disease.","volume":"68","author":"Schmitt","year":"2019","journal-title":"Gut"},{"key":"2022051713564643300_CIT0026","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1016\/j.jid.2019.05.016","article-title":"Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study.","volume":"139","author":"Gordon","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2022051713564643300_CIT0027","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaci.2018.07.028","article-title":"Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab.","volume":"143","author":"Brunner","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2022051713564643300_CIT0028","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/gutjnl-2019-318483","article-title":"Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells.","volume":"69","author":"Powell","year":"2020","journal-title":"Gut"},{"key":"2022051713564643300_CIT0029","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjab190\/41029806\/jjab190.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/Supplement_2\/ii73\/43679571\/jjab190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/Supplement_2\/ii73\/43679571\/jjab190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T13:59:03Z","timestamp":1652795943000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/16\/Supplement_2\/ii73\/6415071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":29,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2021,11,1]]},"published-print":{"date-parts":[[2022,5,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab190","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,1]]},"published":{"date-parts":[[2021,11,1]]}}}